<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478647</url>
  </required_header>
  <id_info>
    <org_study_id>TKT034</org_study_id>
    <secondary_id>2006-006304-11</secondary_id>
    <nct_id>NCT00478647</nct_id>
  </id_info>
  <brief_title>Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase</brief_title>
  <official_title>A Multicenter Open-Label Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire Human Genetic Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme
      glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside
      accumulates within macrophages leading to cellular engorgement, organomegaly, and organ
      system dysfunction. The purpose of this study is to evaluate the safety and efficacy of every
      other week dosing of GA-GCB (velaglucerase alfa) in participants with type 1 Gaucher disease
      who were previously treated with imiglucerase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and
      does not involve the CNS. Typical manifestations of type 1 Gaucher disease include
      hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism,
      skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life.
      Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a
      continuous human cell line using proprietary gene-activation technology and has an identical
      amino acid sequence to the naturally occurring human enzyme. GA-GCB contains terminal mannose
      residues that target the enzyme to the macrophages-the primary target cells in Gaucher
      disease. This study was designed to determine the safety of GA-GCB in men, women, and
      children with Type 1 Gaucher disease who were previously treated with imiglucerase. Each
      participant's duration of treatment will be 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>Week 53</time_frame>
    <description>Safety was assessed throughout the study by assessments including adverse events, concomitant medication use, and vital signs. Additional safety assessments, including 12-lead ECGs, physical examinations, clinical laboratory tests and determination of the presence of anti-velaglucerase alfa antibodies.
Refer to Adverse event section for further details.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 53 in Hemoglobin Concentration</measure>
    <time_frame>Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 53 in Platelet Count</measure>
    <time_frame>Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 51 in Normalized Liver Volume</measure>
    <time_frame>Week 51</time_frame>
    <description>Liver volume has been normalized for percentage (%) of body weight. Liver size relative to body weight= (Liver volume [cc]/Body weight [kg])*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 51 in Normalized Spleen Volume</measure>
    <time_frame>Week 51</time_frame>
    <description>Spleen volume has been normalized for percentage (%) of body weight. Spleen size relative to body weight= (Spleen volume [cc]/Body weight [kg])*100</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gaucher Disease, Type 1</condition>
  <arm_group>
    <arm_group_label>GA-GCB (velaglucerase alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GA-GCB (velaglucerase alfa)</intervention_name>
    <description>15-60 U/kg, every other week via intravenous infusion</description>
    <arm_group_label>GA-GCB (velaglucerase alfa)</arm_group_label>
    <other_name>VPRIV®</other_name>
    <other_name>GA-GCB</other_name>
    <other_name>gene-activated® human glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Includes:

          -  The participant has a documented diagnosis of type 1 Gaucher disease, as determined by
             deficient glucocerebrosidase (GCB) activity relative to normal as measured in
             leukocytes or by genotype analysis and the participant/legal guardian is willing and
             able to provide written informed consent prior to initiating any study-related
             procedures

          -  The participant has received consistent treatment with imiglucerase at a dose ≤ 60
             U/kg and ≥ 15 U/kg every other week for a minimum of 30 consecutive months.
             Participants who are anti-imiglucerase antibody positive will be allowed to enter this
             study

          -  The participant is at least 2 years of age

          -  Female participants of child-bearing potential agree to use a medically acceptable
             method of contraception. Male participants must agree to use a medically acceptable
             method of birth control

          -  Participant must be sufficiently co-operative to participate in the study as judged by
             the Investigator.

        Exclusion Criteria:

        Includes:

          -  The participant has type 2 or 3 Gaucher disease or is suspected of having type 3
             Gaucher disease

          -  The participant has received treatment with any investigational drug or device within
             the 30 days prior to study entry; such use during the study is not permitted

          -  Participant is HIV positive

          -  Participant is hepatitis B/C positive

          -  The participant presents with sustained iron, folic acid and/or vitamin B12
             deficiency-related anemia during Screening

          -  The participant, participant's parent(s), or participant's legal guardian(s) is/are
             unable to understand the nature, scope, and possible consequences of the study

          -  The participant has a significant comorbidity that might affect study data or confound
             the study results

          -  The participant is unable to comply with the protocol or is otherwise unlikely to
             complete the study, as determined by the Investigator

          -  The participant has experienced an anaphylactic/anaphylactoid reaction during
             treatment with imiglucerase

          -  The participant has received miglustat during the 6 months prior to study enrollment

          -  The participant has an active, clinically significant spleen infarction

          -  The participant has active, progressive bone necrosis

          -  The participant is a pregnant and/or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Crombez, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shire Human Genetic Therapies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Tylki-Szmanska, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Memorial Health Institute, Warszawa, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Charrow, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feinberg School of Medicine, Chicago, Illinois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurie Smith, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital and Clinic, Kansas City, Missouri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ari Zimran, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Eng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Children's Hospital, Houston, Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Fernhoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University, Decatur, Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Grabowski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinatti Children's Hospital, Cincinnati, Ohio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Harmatz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Oakland, Oakland, California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret Heisel Kurth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chidlren's of Minnesota, Minneapolis, Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Longo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Genetics/Pediatrics, Salt Lake City, Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Mardach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Metabolic Center, Los Angeles, California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Pastores, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine, New York, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William J. Rhead, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Wisconsin, Milwaukee, Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athul Mehta, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Free Hosptial, London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Giraldo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Miguel Servet, Zaragoza, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Metabolic Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital and Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinatti Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Genetics/Pediatrics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Health Institute</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>500009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2007</study_first_posted>
  <results_first_submitted>August 4, 2010</results_first_submitted>
  <results_first_submitted_qc>August 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2010</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzyme Replacement Therapy</keyword>
  <keyword>Gaucher disease</keyword>
  <keyword>glucocerebrosidase</keyword>
  <keyword>beta-glucocerebrosidase</keyword>
  <keyword>Acid beta-glucocerebrosidase</keyword>
  <keyword>glucosylceramidase</keyword>
  <keyword>D-glucosyl-N-acylsphingosine glucohydrolase</keyword>
  <keyword>gene activation</keyword>
  <keyword>human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant was enrolled on 25 July 2007 and the last participant completed on 26 June 2009. Participants received the same dose of velaglucerase alfa (GA-GCB) as their previous dose of imiglucerase (range- &lt;/= 60 Unit per kilogram (U/kg) - &gt;/=15 U/kg) every other week via intravenous infusion.</recruitment_details>
      <pre_assignment_details>Participant at least 2 years old with documented diagnosis of type 1 Gaucher disease.Consistent treatment(every other week at a dose ≤/= 60 U/kg and ≥/= 15 U/kg) with imiglucerase for a minimum of 30 consecutive months;same dose during the 6 months prior to study enrollment.Minor dosing interval variance was allowed per standard clinical practice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GA-GCB (Velaglucerase Alfa)</title>
          <description>15-60 U/kg, every other week via intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38">Intent-to-Treat (ITT)=participants who have received at least 1 full or partial dose of study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GA-GCB (Velaglucerase Alfa)</title>
          <description>15-60 U/kg, every other week via intravenous infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="18.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline hemoglobin concentration</title>
          <units>gram per deciliter (g/dL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.775" lower_limit="10.40" upper_limit="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline liver volume</title>
          <units>Percent (%) body weight</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.90" lower_limit="1.4" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline platelet count</title>
          <units>10^9 per liter (10^9/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.00" lower_limit="29.0" upper_limit="399.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline spleen volume</title>
          <units>Percent (%) body weight</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.50" lower_limit="0.2" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 53 in Hemoglobin Concentration</title>
        <time_frame>Week 53</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>GA-GCB (Velaglucerase Alfa)</title>
            <description>15-60 U/kg, every other week via intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 53 in Hemoglobin Concentration</title>
          <population>ITT population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.101" lower_limit="-0.272" upper_limit="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 53 in Platelet Count</title>
        <time_frame>Week 53</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>GA-GCB (Velaglucerase Alfa)</title>
            <description>15-60 U/kg, every other week via intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 53 in Platelet Count</title>
          <population>ITT population.</population>
          <units>percent (%) change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.04" lower_limit="0.54" upper_limit="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 51 in Normalized Liver Volume</title>
        <description>Liver volume has been normalized for percentage (%) of body weight. Liver size relative to body weight= (Liver volume [cc]/Body weight [kg])*100</description>
        <time_frame>Week 51</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>GA-GCB (Velaglucerase Alfa)</title>
            <description>15-60 U/kg, every other week via intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 51 in Normalized Liver Volume</title>
          <description>Liver volume has been normalized for percentage (%) of body weight. Liver size relative to body weight= (Liver volume [cc]/Body weight [kg])*100</description>
          <population>ITT population.</population>
          <units>Percent (%) change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-2.62" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 51 in Normalized Spleen Volume</title>
        <description>Spleen volume has been normalized for percentage (%) of body weight. Spleen size relative to body weight= (Spleen volume [cc]/Body weight [kg])*100</description>
        <time_frame>Week 51</time_frame>
        <population>ITT population. Four splenectomized participants were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>GA-GCB (Velaglucerase Alfa)</title>
            <description>15-60 U/kg, every other week via intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 51 in Normalized Spleen Volume</title>
          <description>Spleen volume has been normalized for percentage (%) of body weight. Spleen size relative to body weight= (Spleen volume [cc]/Body weight [kg])*100</description>
          <population>ITT population. Four splenectomized participants were excluded.</population>
          <units>Percent (%) change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" lower_limit="-10.77" upper_limit="-0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Experienced at Least One Adverse Event</title>
        <description>Safety was assessed throughout the study by assessments including adverse events, concomitant medication use, and vital signs. Additional safety assessments, including 12-lead ECGs, physical examinations, clinical laboratory tests and determination of the presence of anti-velaglucerase alfa antibodies.
Refer to Adverse event section for further details.</description>
        <time_frame>Week 53</time_frame>
        <population>Safety population included subjects who have received at least 1 full or partial dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>GA-GCB (Velaglucerase Alfa)</title>
            <description>15-60 U/kg, every other week via intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Experienced at Least One Adverse Event</title>
          <description>Safety was assessed throughout the study by assessments including adverse events, concomitant medication use, and vital signs. Additional safety assessments, including 12-lead ECGs, physical examinations, clinical laboratory tests and determination of the presence of anti-velaglucerase alfa antibodies.
Refer to Adverse event section for further details.</description>
          <population>Safety population included subjects who have received at least 1 full or partial dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of informed consent until 30 days after the last dose and/or until the event was resolved/stabilized or outcome was reached, whichever came first. Participants who discontinued/withdrew prior to Week 53, and followed up to 30 days after last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GA-GCB (Velaglucerase Alfa)</title>
          <description>15-60 U/kg, every other week via intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="33" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Non-Cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="12" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shire's agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ≤180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial's multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tiffany Crump</name_or_title>
      <organization>Shire HGT</organization>
      <phone>484-595-8850</phone>
      <email>tcrump@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

